keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/28697559/depressive-symptoms-and-tau-accumulation-in-the-inferior-temporal-lobe-and-entorhinal-cortex-in-cognitively-normal-older-adults-a-pilot-study
#1
Jennifer R Gatchel, Nancy J Donovan, Joseph J Locascio, Aaron P Schultz, J Alex Becker, Jasmeer Chhatwal, Kathryn V Papp, Rebecca E Amariglio, Dorene M Rentz, Deborah Blacker, Reisa A Sperling, Keith A Johnson, Gad A Marshall
BACKGROUND: Depressive symptoms are common in older adults and associated with increased morbidity and cognitive decline. These symptoms occur during preclinical and prodromal stages of Alzheimer's disease (AD), but their relationship to tau, one of the main AD proteinopathies, is poorly understood. OBJECTIVE: The objective of this study was to investigate the cross-sectional association between depressive symptoms and cerebral tau [18F T807 (also known as 18F-AV-1451) tau positron emission tomography (PET) imaging] in cognitively normal (CN) older adults...
July 4, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28690634/preventive-effect-of-rifampicin-on-alzheimer-disease-needs-at-least-450-mg-daily-for-1-year-an-fdg-pet-follow-up-study
#2
Tomomichi Iizuka, Kozo Morimoto, Yuka Sasaki, Masashi Kameyama, Atsuyuki Kurashima, Kazumasa Hayasaka, Hideo Ogata, Hajime Goto
BACKGROUND: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed (18)F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. METHODS: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled...
May 2017: Dementia and Geriatric Cognitive Disorders Extra
https://www.readbyqxmd.com/read/28689050/self-reported-traumatic-brain-injury-and-in-vivo-measure-of-ad-vulnerable-cortical-thickness-and-ad-related-biomarkers-in-the-adni-cohort
#3
Ming-Liang Wang, Xiao-Er Wei, Meng-Meng Yu, Peng-Yang Li, Wen-Bin Li
In this study, we aimed to investigate whether self-reported mild traumatic brain injury (mTBI) was associated with decreased AD-vulnerable cortical thickness, and to assess the relationship between AD-vulnerable cortical thickness and AD-related biomarker in the Alzheimer's Disease Neuroimaging Initiative subjects. We identified 45 self-reported mTBI subjects, who had structural MRI, 18F-AV45 PET, and cerebrospinal fluid (CSF) data. Of them, eight subjects were normal; ten were preclinical AD; seventeen were MCI due to AD; ten were AD...
July 5, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28654263/identification-of-three-novel-radiotracers-for-imaging-aggregated-tau-in-alzheimer-s-disease-with-positron-emission-tomography
#4
Luca C Gobbi, Henner Knust, Matthias Körner, Michael Honer, Christian Czech, Sara Belli, Dieter Muri, Martin R Edelmann, Thomas Hartung, Isabella Erbsmehl, Sandra Grall-Ulsemer, Andreas Koblet, Marianne Rueher, Sandra Steiner, Hayden T Ravert, William B Mathews, Daniel P Holt, Hiroto Kuwabara, Heather Valentine, Robert F Dannals, Dean F Wong, Edilio Borroni
Aggregates of tau and beta amyloid (Aβ) plaques constitute the histopathological hallmarks of Alzheimer's disease and are prominent targets for novel therapeutics as well as for biomarkers for diagnostic in vivo imaging. In recent years much attention has been devoted to the discovery and development of new PET tracers to image tau aggregates in the living human brain. Access to a selective PET tracer to image and quantify tau aggregates represents a unique tool to support the development of any novel therapeutic agent targeting pathological forms of tau...
June 27, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28652213/the-efficacy-of-18-f-fdg-pet-ct-and-67-ga-spect-ct-in-diagnosing-fever-of-unknown-origin
#5
Bor-Tau Hung, Pei-Wen Wang, Yu-Jih Su, Wen-Chi Huang, Yen-Hsiang Chang, Shu-Hua Huang, Chiung-Chih Chang
OBJECTIVE: Fever of unknown origin (FUO) is a diagnostic challenge. This study aimed to assess the efficacy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) and gallium-67 single-photon emission computed tomography/computed tomography ((67)Ga SPECT/CT) in diagnosing FUO. METHODS: A total of 68 patients with FUO underwent (18)F-FDG PET/CT and (67)Ga SPECT/CT from January 2013 through May 2016. Images were read independently...
June 23, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28645685/concordance-between-brain-18-f-fdg-pet-and-cerebrospinal-fluid-biomarkers-in-diagnosing-alzheimer-s-disease
#6
S Rubí, A Noguera, S Tarongí, M Oporto, A García, H Vico, A Espino, M J Picado, A Mas, C Peña, G Amer
OBJECTIVES: Cortical posterior hypometabolism on PET imaging with (18)F-FDG (FDG-PET), and altered levels of Aß1-42 peptide, total Tau (tTau) and phosphorylated Tau (pTau) proteins in cerebrospinal fluid (CSF) are established diagnostic biomarkers in Alzheimer's disease (AD). An evaluation has been made of the concordance and relationship between the results of FDG-PET and CSF biomarkers in symptomatic patients with suspected AD. MATERIAL AND METHODS: A retrospective review was carried out on 120 patients with cognitive impairment referred to our Cognitive Neurology Unit, and who were evaluated by brain FDG-PET and a lumbar puncture for CSF biomarkers...
June 20, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28640595/detection-and-characterization-of-small-molecule-interactions-with-fibrillar-protein-aggregates-using-microscale-thermophoresis
#7
Emily Fisher, Yanyan Zhao, Robert Richardson, Malgorzata Janik, Alexander K Buell, Franklin I Aigbirhio, Gergely Tóth
Neurodegenerative diseases such as Parkinson's and Alzheimer's disease share the pathological hallmark of fibrillar protein aggregates. The specific detection of these protein aggregates by positron emission tomography (PET) in the patient brain can yield valuable information for diagnosis and disease progression. However, the identification of novel small compounds that bind fibrillar protein aggregates has been a challenge. In this study, microscale thermophoresis (MST) was applied to assess the binding affinity of known small molecule ligands of α-synuclein fibrils, which were also tested in parallel in a thioflavin T fluorescence competition assay for further validation...
July 6, 2017: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/28639126/a-comparison-of-five-partial-volume-correction-methods-for-tau-and-amyloid-pet-imaging-with-18-f-thk5351-and-11-c-pib
#8
Miho Shidahara, Benjamin A Thomas, Nobuyuki Okamura, Masanobu Ibaraki, Keisuke Matsubara, Senri Oyama, Yoichi Ishikawa, Shoichi Watanuki, Ren Iwata, Shozo Furumoto, Manabu Tashiro, Kazuhiko Yanai, Kohsuke Gonda, Hiroshi Watabe
PURPOSE: To suppress partial volume effect (PVE) in brain PET, there have been many algorithms proposed. However, each methodology has different property due to its assumption and algorithms. Our aim of this study was to investigate the difference among partial volume correction (PVC) method for tau and amyloid PET study. METHODS: We investigated two of the most commonly used PVC methods, Müller-Gärtner (MG) and geometric transfer matrix (GTM) and also other three methods for clinical tau and amyloid PET imaging...
June 21, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28612291/-f-18-av-1451-binding-correlates-with-postmortem-neurofibrillary-tangle-braak-staging
#9
Marta Marquié, Michael Siao Tick Chong, Alejandro Antón-Fernández, Eline E Verwer, Nil Sáez-Calveras, Avery C Meltzer, Prianca Ramanan, Ana C Amaral, Jose Gonzalez, Marc D Normandin, Matthew P Frosch, Teresa Gómez-Isla
[F-18]-AV-1451, a PET tracer specifically developed to detect brain neurofibrillary tau pathology, has the potential to facilitate accurate diagnosis of Alzheimer's disease (AD), staging of brain tau burden and monitoring disease progression. Recent PET studies show that patients with mild cognitive impairment and AD dementia exhibit significantly higher in vivo [F-18]-AV-1451 retention than cognitively normal controls. Importantly, PET patterns of [F-18]-AV-1451 correlate well with disease severity and seem to match the predicted topographic Braak staging of neurofibrillary tangles (NFTs) in AD, although this awaits confirmation...
June 13, 2017: Acta Neuropathologica
https://www.readbyqxmd.com/read/28587897/comparison-of-multiple-tau-pet-measures-as-biomarkers-in-aging-and-alzheimer-s-disease
#10
Anne Maass, Susan Landau, Suzanne L Baker, Andy Horng, Samuel N Lockhart, Renaud La Joie, Gil D Rabinovici, William J Jagust
The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal...
June 3, 2017: NeuroImage
https://www.readbyqxmd.com/read/28584971/f-18-fdg-and-f-18-tau-pet-in-posterior-cortical-atrophy
#11
Madhavi Tripathi, Abhinav Bansal, Vivek Baghel, Praveen Kumar, Chandrasekhar Bal
No abstract text is available yet for this article.
June 6, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28583275/benign-cutaneous-and-subcutaneous-lesions-on-fdg-pet-ct
#12
REVIEW
Ur Metser, Noam Tau
(18)F-FDG, the most commonly used PET radiopharmaceutical in clinical practice, can also accumulate in inflammatory and infectious conditions. This may account for false-positive PET findings when staging or restaging a patient with malignancy. As clinical use of FDG-PET-CT is increasing, nuclear medicine physicians are encountering a myriad of cutaneous and subcutaneous lesions, many of which are incidental and benign. The most common cause for the FDG avidity of these lesions is inflammation. Although a specific diagnosis may not always be possible, background clinical history and morphologic features of the lesion on CT may help narrow the differential diagnosis...
July 2017: Seminars in Nuclear Medicine
https://www.readbyqxmd.com/read/28576172/multimodal-pet-imaging-of-amyloid-and-tau-pathology-in-alzheimer-disease-and-non-alzheimer-disease-dementias
#13
REVIEW
Chenjie Xia, Bradford C Dickerson
Biomarkers of the molecular pathology underpinning dementia syndromes are increasingly recognized as crucial for diagnosis and development of disease-modifying treatments. Amyloid PET imaging is an integral part of the diagnostic assessment of Alzheimer disease. Its use has also deepened understanding of the role of amyloid pathology in Lewy body disorders and aging. Tau PET imaging is an imaging biomarker that will likely play an important role in the diagnosis, monitoring, and treatment in dementias. Using tau PET imaging to examine how tau pathology relates to amyloid and other markers of neurodegeneration will serve to better understand the pathophysiologic cascade that leads to dementia...
July 2017: PET Clinics
https://www.readbyqxmd.com/read/28576171/pet-imaging-for-early-detection-of-alzheimer-s-disease-from-pathologic-to-physiologic-biomarkers
#14
REVIEW
Weiqi Bao, Hongmei Jia, Sjoerd Finnema, Zhengxin Cai, Richard E Carson, Yiyun Henry Huang
This article describes the application of various PET imaging agents in the investigation and diagnosis of Alzheimer's disease (AD), including radiotracers for pathologic biomarkers of AD such as β-amyloid deposits and tau protein aggregates, and the neuroinflammation biomarker 18 kDa translocator protein, as well as physiologic biomarkers, such as cholinergic receptors, glucose metabolism, and the synaptic density biomarker synaptic vesicle glycoprotein 2A. Potential of these biomarkers for early AD diagnosis is also assessed...
July 2017: PET Clinics
https://www.readbyqxmd.com/read/28568506/pbb3-imaging-in-parkinsonian-disorders-evidence-for-binding-to-tau-and-other-proteins
#15
Alexandra Perez-Soriano, Julieta E Arena, Katie Dinelle, Qing Miao, Jessamyn McKenzie, Nicole Neilson, Andreas Puschmann, Paul Schaffer, Hitoshi Shinotoh, Jenna Smith-Forrester, Elham Shahinfard, Nasim Vafai, Daryl Wile, Zbigniew Wszolek, Makoto Higuchi, Vesna Sossi, A Jon Stoessl
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy. METHODS: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [(11) C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region...
July 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28558094/hierarchical-organization-of-tau-and-amyloid-deposits-in-the-cerebral-cortex
#16
Jorge Sepulcre, Michel J Grothe, Mert Sabuncu, Jasmeer Chhatwal, Aaron P Schultz, Bernard Hanseeuw, Georges El Fakhri, Reisa Sperling, Keith A Johnson
Importance: Abnormal accumulation of tau and amyloid-β (Aβ) proteins in the human brain are 2 pathologic hallmarks of Alzheimer disease (AD). Because pathologic processes begin decades before the onset of the clinical manifestations, the study of the cortical distribution of early-stage pathologic alterations is critical in understanding the underpinnings of the disease. Objectives: To identify the in vivo brain spatial distributions of tau and Aβ deposits in a sample of cognitively normal participants in the Harvard Aging Brain Study, determine spatial patterns of pathologic alterations, and provide means for improved individual in vivo staging...
July 1, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28545932/the-association-between-tau-pet-and-retrospective-cortical-thinning-in-clinically-normal-elderly
#17
Molly R LaPoint, Jasmeer P Chhatwal, Jorge Sepulcre, Keith A Johnson, Reisa A Sperling, Aaron P Schultz
Tau pathology has been associated with neuronal loss at autopsy, but the temporal evolution of tau pathology and atrophy remains unclear. Here, we investigate the association between cross-sectional AV-1451-PET as a marker of tau pathology and cortical thickness cross-sectionally. We also investigated retrospective rates of cortical thinning over the three years preceding the AV-1451 scan in a clinically normal cohort of 103 older adults from the Harvard Aging Brain Study. Tau measurements were Geometric Transfer Matrix partial volume corrected standardized uptake value ratios (SUVRs) with a cerebellar gray reference region...
May 22, 2017: NeuroImage
https://www.readbyqxmd.com/read/28507319/longitudinal-changes-of-tau-pet-imaging-in-relation-to-hypometabolism-in-prodromal-and-alzheimer-s-disease-dementia
#18
K Chiotis, L Saint-Aubert, E Rodriguez-Vieitez, A Leuzy, O Almkvist, I Savitcheva, M Jonasson, M Lubberink, A Wall, G Antoni, A Nordberg
The development of tau-specific positron emission tomography (PET) tracers allows imaging in vivo the regional load of tau pathology in Alzheimer's disease (AD) and other tauopathies. Eighteen patients with baseline investigations enroled in a 17-month follow-up study, including 16 with AD (10 had mild cognitive impairment and a positive amyloid PET scan, that is, prodromal AD, and six had AD dementia) and two with corticobasal syndrome. All patients underwent PET scans with [(18)F]THK5317 (tau deposition) and [(18)F]FDG (glucose metabolism) at baseline and follow-up, neuropsychological assessment at baseline and follow-up and a scan with [(11)C]PIB (amyloid-β deposition) at baseline only...
May 16, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28500751/radiological-biomarkers-for-diagnosis-in-psp-where-are-we-and-where-do-we-need-to-be
#19
REVIEW
Jennifer L Whitwell, Günter U Höglinger, Angelo Antonini, Yvette Bordelon, Adam L Boxer, Carlo Colosimo, Thilo van Eimeren, Lawrence I Golbe, Jan Kassubek, Carolin Kurz, Irene Litvan, Alexander Pantelyat, Gil Rabinovici, Gesine Respondek, Axel Rominger, James B Rowe, Maria Stamelou, Keith A Josephs
PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. A large body of neuroimaging research has been conducted over the past two decades, with many studies proposing different structural MRI and molecular PET/SPECT biomarkers for PSP. These include measures of brainstem, cortical and striatal atrophy, diffusion weighted and diffusion tensor imaging abnormalities, [18F] fluorodeoxyglucose PET hypometabolism, reductions in striatal dopamine imaging and, most recently, PET imaging with ligands that bind to tau...
July 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28487650/neuropsychological-testing-and-machine-learning-distinguish-alzheimer-s-disease-from-other-causes-for-cognitive-impairment
#20
Pavel Gurevich, Hannes Stuke, Andreas Kastrup, Heiner Stuke, Helmut Hildebrandt
With promising results in recent treatment trials for Alzheimer's disease (AD), it becomes increasingly important to distinguish AD at early stages from other causes for cognitive impairment. However, existing diagnostic methods are either invasive (lumbar punctures, PET) or inaccurate Magnetic Resonance Imaging (MRI). This study investigates the potential of neuropsychological testing (NPT) to specifically identify those patients with possible AD among a sample of 158 patients with Mild Cognitive Impairment (MCI) or dementia for various causes...
2017: Frontiers in Aging Neuroscience
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"